A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Apolipoprotein C-III (apoC-III) inhibits triglyceride hydrolysis and has been implicated in coronary artery disease. Through a genome-wide association study, we have found that about 5% of the Lancaster Amish are heterozygous carriers of a null mutation (R19X) in the gene encoding apoC-III ( APOC3 ) and, as a result, express half the amount of apoC-III present in noncarriers. Mutation carriers compared with noncarriers had lower fasting and postprandial serum triglycerides, higher levels of HDL-cholesterol and lower levels of LDL-cholesterol. Subclinical atherosclerosis, as measured by coronary artery calcification, was less common in carriers than noncarriers, which suggests that lifelong deficiency of apoC-III has a cardioprotective effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function variants of APOC3 that result in reduced synthesis of the protein are associated with absent or low circulating apoCIII levels, increased efficiency of TG removal from TRL, and lower plasma TG levels,59,60”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, rare heterozygous LOF variants in APOC3 encoding apo C-III are associated with ∼50% reduced TG levels and significantly increased clearance of very-low-density lipoprotein (VLDL).8,9”
From Clinical review on triglycerides (2020) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and is a genetically validated target to reduce ASCVD risk.8–10,64–66”
From Clinical review on triglycerides (2020) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Founder populations (such as those from Finland and Iceland) have provided multiple examples of otherwise rare risk alleles driven to higher frequency locally through drift and/or selection49–52.”
From A brief history of human disease genetics (2020) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apolipoprotein C-III is a central regulator of triglyceride metabolism that limits the clearance of triglyceride-rich lipoproteins through inhibition of lipoprotein lipase and hepatic uptake of triglyceride-rich lipoprotein remnants. 6-8”
From Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia (2025) · cites this paper as [7]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups
Detrano, R., Guerci, A. D., Carr, J. J., Bild, D. E., Burke, G., Folsom, A. R., Liu, K., Shea, S., Szklo, M., Bluemke, D. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa072100 · Cited by 2,989
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Goldstein, J. L., Schrott, H. G., Hazzard, W. R., Bierman, E. L., & Motulsky, A. G. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107332 · Cited by 1,443
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Cited by
Items 301–400 of 682
Johns, N., Tan, B. H. L., Macmillan, M. T., Solheim, T. S., Ross, J. A. F., Baracos, V. E., Damaraju, S., & Fearon, K. C. H. (2014) · Journal of Genetics · doi:10.1007/s12041-014-0405-9 · Cited by 32
Taskinen, M., Björnson, E., Matikainen, N., Söderlund, S., Rämö, J. T., Ainola, M., Hakkarainen, A., Sihlbom, C., Thorsell, A., Andersson, L. K., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.160607 · Cited by 31
“Interestingly, 5% of the Lancaster Amish are heterozygous carriers for this null mutation (29).”
Using genetically isolated populations to understand the genomic basis of disease
Zeggini, E. (2014) · Genome Medicine · doi:10.1186/s13073-014-0083-5 · Cited by 30
“[7] reported a missense variant (R19X) that abolishes expression of the”
BackgroundAPOC3 induces endothelial dysfunction through TNF-α and JAM-1
Tao, Y., Xiong, Y.-S., Wang, H., Chu, S.-P., Zhong, R., Wang, J., Wang, G., Ren, X., & Yu, J. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0326-0 · Cited by 33
Cohort-wide deep whole genome sequencing and the allelic architecture of complex traits
Gilly, A., Suveges, D., Kuchenbaecker, K., Pollard, M., Southam, L., Hatzikotoulas, K., Farmaki, A.-E., Bjornland, T., Waples, R., Appel, E. V. R., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07070-8 · Cited by 29
Mulvihill, E. E. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000495 · Cited by 29
Genetic control of the mouse HDL proteome defines HDL traits, function, and heterogeneity
Pamir, N., Pan, C., Plubell, D. L., Hutchins, P. M., Tang, C., Wimberger, J., Irwin, A. D., Vallim, T. Q. D. A., Heinecke, J. W., & Lusis, A. J. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m090555 · Cited by 30
“On the other hand, humans with an APOC3 mutation benefit from a favorable lipoprotein profile, increased insulin sensitivity, lower incidence of hypertension, and protection against cardiovascular diseases (68) (69) (70) .”
BackgroundRNA-based therapy in the management of lipid disorders: a review
Blom, D. J., Marais, A. D., Moodley, R., van der Merwe, N., van Tonder, A., & Raal, F. J. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01649-3 · Cited by 31
Hopkins, P. N., Nanjee, M. N., Wu, L. L., McGinty, M. G., Brinton, E. A., Hunt, S. C., & Anderson, J. L. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.05.016 · Cited by 29
“A null mutation in apo CIII may offer protection from both [59].”
BackgroundMillar, J. S., & Lagor, W. R. (2009) · Journal of Receptor Ligand and Channel Research · doi:10.2147/jrlcr.s6033 · Cited by 40
“Carriers of rare null mutation in the apoC-III gene have apoC-III levels in plasma that are half the normal concentration.(80) These individuals have lower than normal levels of LDL cholesterol and triglyceride.”
Backman, J., Yerges-Armstrong, L. M., Horenstein, R. B., Newcomer, S., Shaub, S., Morrisey, M., Donnelly, P., Drolet, M., Tanner, K., Pavlovich, M., et al. (2017) · Clinical and Translational Science · doi:10.1111/cts.12438 · Cited by 28
Self-citationQuantile-dependent expressivity of postprandial lipemia
Williams, P. T. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229495 · Cited by 29
Soh, J., Josekutty, J., & Hussain, M. M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0974-2.00017-8 · Cited by 30
Hu, S., Cui, G., Huang, J., Jiang, J.-G., & Wang, D. W. (2016) · Scientific Reports · doi:10.1038/srep32700 · Cited by 30
Radwan, Z. H., Wang, X., Waqar, F., Pirim, D., Niemsiri, V., Hokanson, J. E., Hamman, R. F., Bunker, C. H., Barmada, M. M., Demirci, F. Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114618 · Cited by 27
Kraaijenhof, J. M., Kerkvliet, M., Nurmohamed, N. S., Grefhorst, A., Kroon, J., Wareham, N. J., Hovingh, G. K., Stroes, E. S. G., Boekholdt, S. M., & Reeskamp, L. F. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf037 · Cited by 33
Fu, J. M., Kwok, S., Sinai, L., Abdel‐Razek, O., Babula, J., Chen, D., Farago, E., Fernandopulle, N., Leith, S. J., Loyzer, M. N., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.01.008 · Cited by 28
Aroner, S. A., Furtado, J. D., Sacks, F. M., Tsai, M. Y., Mukamal, K. J., McClelland, R. L., & Jensen, M. K. (2019) · Diabetologia · doi:10.1007/s00125-019-4847-8 · Cited by 27
The Long Noncoding RNA RP11-728F11.4 Promotes Atherosclerosis
Dong, X.-H., Lu, Z., Kang, C., Li, X.-H., Haworth, K. E., Ma, X., Lu, J., Liu, X., Fang, F., Wang, C. S., et al. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315114 · Cited by 29
Lightbourne, M., Startzell, M. S., Bruce, K. D., Brite, B., Muniyappa, R., Skarulis, M. C., Shamburek, R. D., Gharib, A. M., Ouwerkerk, R., Walter, M. F., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.06.011 · Cited by 27
Spagnuolo, C. M., & Hegele, R. A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2206015 · Cited by 28
“Thereafter, studies in the Amish population showed that individuals with reduced apo C-III due to a null allele from a premature truncation had, compared to controls, a markedly improved lipid profile and reduced preclinical atherosclerosis on vascular imaging [22].”
BackgroundPirruccello, J. P., & Kathiresan, S. (2010) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328338574d · Cited by 30
Kenny, E. E., Kim, M., Gusev, A., Lowe, J. K., Salit, J., Smith, J. G., Kovvali, S., Kang, H. M., Newton‐Cheh, C., Daly, M. J., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq510 · Cited by 31
Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition
Meyers, N. L., Larsson, M., Vorrsjö, E., Olivecrona, G., & SMALL, D. M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m071126 · Cited by 30
Oniciu, D. C., Hashiguchi, T., Shibazaki, Y., & Bisgaier, C. L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194568 · Cited by 28
Apolipoprotein CIII is a new player in diabetes
Juntti‐Berggren, L., & Berggren, P. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000372 · Cited by 30
Global genetic diversity of human apolipoproteins and effects on cardiovascular disease risk
Zhou, Y., Mägi, R., Milani, L. A., & Lauschke, V. M. (2018) · Journal of Lipid Research · doi:10.1194/jlr.p086710 · Cited by 31
“Most alleles exhibited large interethnic differences in frequencies, indicating that accurate genetic prediction of dyslipidemia and CVD risk requires population-specific genotyping strategies.”
BackgroundInfluentialBendjilali, N., Hsueh, W.-C., He, Q., Willcox, D. C., Nievergelt, C. M., Donlon, T. A., Kwok, P., Suzuki, M., & Willcox, B. J. (2014) · The Journals of Gerontology Series A · doi:10.1093/gerona/glt203 · Cited by 33
“This includes studies of Ashkenazi Jews with the cholesteryl ester transfer protein (ceTP) gene and the apolipoprotein C-III (aPoc3) gene (65); Amish, with the aPoc3 (66); Laron Ecuadorians with the growth hormone receptor (GHR) gene (67); and Americans of Japanese and Okinawan ethnicity in Hawaii, with the ceTP gene…”
BackgroundAn Apo-14 Promoter-Driven Transgenic Zebrafish That Marks Liver Organogenesis
Wang, R., Li, Z., Wang, Y., & Gui, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022555 · Cited by 27
Backman, J., O’Connell, J. R., Tanner, K., Peer, C. J., Figg, W. D., Spencer, S. D., Mitchell, B. D., Shuldiner, A. R., Yerges‐Armstrong, L. M., Horenstein, R. B., et al. (2017) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000272 · Cited by 26
Self-citationγ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor
Kim, K., Goldberg, I. J., Graham, M. J., Sundaram, M., Bertaggia, E., Lee, S. X., Qiang, L., Haeusler, R. A., Metzger, D., Chambon, P., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.010 · Cited by 26
Emerging Targets for Cardiovascular Disease Prevention in Diabetes
Stitziel, N. O., Kanter, J. E., & Bornfeldt, K. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.03.011 · Cited by 30
Hyperalphalipoproteinemia and Beyond: The Role of HDL in Cardiovascular Diseases
Giammanco, A., Noto, D., Barbagallo, C. M., Nardi, E., Caldarella, R., Ciaccio, M., Averna, M. R., & Cefalu, A. B. (2021) · Life · doi:10.3390/life11060581 · Cited by 31
“Loss of function of APO-CIII gene mutation carriers exhibits 39% lower plasma TG levels, 22% higher plasma HDL-C levels, 16% lower plasma LDL-C levels, and reduction in CVD risk [84,85].”
BackgroundD’Erasmo, L., Bini, S., & Arca, M. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00967-8 · Cited by 28
APOC3 deficiency: from mice to man
Hofker, M. H. (2009) · European Journal of Human Genetics · doi:10.1038/ejhg.2009.126 · Cited by 28
Zhou, H., Ding, X., Yang, Q., Chen, S., Li, Y., Zhou, X., & Wu, S. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026632 · Cited by 25
Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular events
Raggi, P., Becciu, M. L., & Navarese, E. P. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000921 · Cited by 27
Sahebkar, A., Simental-Mendía, L. E., Katsiki, N., Reiner, Ž., Banach, M., Pirro, M., & Atkin, S. L. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-021508 · Cited by 25
Gilly, A., Ritchie, G. R. S., Southam, L., Farmaki, A., Tsafantakis, E., Dedoussis, G. V., & Zeggini, E. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw088 · Cited by 28
Loss of Transcription Factor CREBH Accelerates Diet-Induced Atherosclerosis in Ldlr −/− Mice
Park, J., Xu, X., Cho, S., & Lee, A. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307790 · Cited by 26
“Deficiencies of LPL inhibitors, such as apolipoprotein C (apoC)-III or angiopoietin-like proteins, conferred protective effects against atherosclerosis.(18,19) In contrast, it has been shown that the loss of apoC-II LPL activator increased the risk of CVD in parallel with plasma TG and cholesterol levels.”
BackgroundSahebkar, A., Simental‐Mendía, L. E., Mikhailidis, D. P., Pirro, M., Banach, M., Sirtori, C. R., Ruscica, M., & Reiner, Ž. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.01.008 · Cited by 25
Butler, A. A., Price, C. A., Graham, J. L., Stanhope, K. L., King, S. M., Hung, Y.-H., Sethupathy, P., Wong, S. C., Hamilton, J., Krauss, R. M., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m089508 · Cited by 25
Pirim, D., Radwan, Z. H., Wang, X., Niemsiri, V., Hokanson, J. E., Hamman, R. F., Feingold, E., Bunker, C. H., Demirci, F. Y., & Kamboh, M. I. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214060 · Cited by 26
Volanesorsen for treatment of familial chylomicronemia syndrome
Lazarte, J., & Hegele, R. A. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.1955348 · Cited by 26
“along with higher levels of HDL cholesterol and reduced subclinical atherosclerosis in a Lancaster Amish cohort [45].”
BackgroundInhibition of ApoCIII: the next PCSK9?
Moens, S. J. B., van Capelleveen, J. C., & Stroes, E. S. G. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000130 · Cited by 25
Furtado, J. D., Wedel, M. K., & Sacks, F. M. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p021717 · Cited by 24
D’Erasmo, L., Gallo, A., Costanzo, A. D., Bruckert, É., & Arca, M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1787380 · Cited by 25
Two novel mutations in apolipoprotein C3 underlie atheroprotective lipid profiles in families
Bochem, A. E., van Capelleveen, J. C., Dallinga‐Thie, G. M., Schimmel, A. W. M., Motazacker, M. M., Tietjen, I., Singaraja, R. R., Hayden, M. R., Kastelein, J. J. P., Stroes, E. S. G., et al. (2014) · Clinical Genetics · doi:10.1111/cge.12201 · Cited by 24
“(9) confirmed the importance of apoCIII as an independent risk factor for CVD in humans by showing that carriers of a null mutation in APOC3 exhibit 50% of normal plasma apoCIII levels, lower fasting and post-prandial serum TGs and less subclinical atherosclerosis, as measured by the extent of coronary artery calcific…”
BackgroundHansen, J., Fernández, J. A., Notø, A. W., Deguchi, H., Björkegren, J., & Mathiesen, E. B. (2011) · Journal of Lipids · doi:10.1155/2011/271062 · Cited by 26
“Thus, it was particularly important to investigate if the effect was independent of other important modulators of triglycerides such as apolipoproteins CII and C-III [33, 34] and apoE genotype [35, 36].”
BackgroundFasting and Nonfasting Triglycerides in Cardiovascular and Other Diseases
Pitha, J. V., Kovář, J., & Blahová, T. (2015) · Physiological Research · doi:10.33549/physiolres.933196 · Cited by 25
Apolipoprotein C3 induces inflammasome activation only in its delipidated form
Hsu, C.-C., Shao, B., Kanter, J. E., He, Y., Vaisar, T., Witztum, J. L., Snell‐Bergeon, J. K., McInnes, G., Bruse, S., Gottesman, O., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01423-2 · Cited by 28
Seckler, H. S., Park, H.-M., Lloyd-Jones, C., Melani, R. D., Camarillo, J. M., Wilkins, J. T., Compton, P. D., & Kelleher, N. L. (2021) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.1c00026 · Cited by 25
New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
Kim, J. Y., & Kim, N. H. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.23 · Cited by 23
Radoviča-Spalviņa, I., Frīdmanis, D., Vaivade, I., Ņikitina-Zaķe, L., & Kloviņš, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064191 · Cited by 25
“SNP selection Our SNP choice was based on information obtained from the number of candidate gene association and GWA studies [7,10– 18,22–30].”
MethodMass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular disease
Mesaros, C., & Blair, I. A. (2016) · Clinical Proteomics · doi:10.1186/s12014-016-9121-1 · Cited by 27
“This result is consistent with the finding that a genetic defect in the production of ApoC-III is associated with reduced TAGs and reduced atherosclerosis [37].”
Aroner, S. A., Koch, M., Mukamal, K. J., Furtado, J. D., Stein, J. H., Tattersall, M. C., McClelland, R. L., & Jensen, M. K. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007824 · Cited by 23
“Supporting this mechanism, APOC3 genetic variants predictive of reduced CAC have been associated with lower circulating triglyceride levels.(15) Beyond its influence on lipid metabolism, apoC-III may also be involved in atherosclerotic development through the promotion of inflammation.”
Ballantyne, C. M., & Norata, G. D. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf606 · Cited by 26
Genomics of drug target prioritization for complex diseases
Chen, R. K., Duffy, Á., & Do, R. (2025) · Nature Reviews Genetics · doi:10.1038/s41576-025-00904-4 · Cited by 30
Lin, J. J., Khetarpal, S. A., Terembula, K., Reilly, M. P., & Wilson, F. P. (2015) · BMC Nephrology · doi:10.1186/s12882-015-0122-5 · Cited by 22
“…on LPA and APOC3 variants have established a causal link be-tween their respective lipoprotein biomarker and increased risk of CV disease, [5, 6, 20, 22, 23] leveraging genetic data as an instrumental variable for CKD risk would more fully address reverse causation and exclude other confounders.”
Islet inflammation in plain sight
Abdulreda, M. H., & Berggren, P. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12160 · Cited by 23
“Consistently, studies show that lowering levels of circulating ApoCIII favours decreased incidence of diabetes and associated complications such as cardiovascular disease [35].”
BackgroundThe Remnant Lipoprotein Hypothesis of Diabetes-Associated Cardiovascular Disease
Bornfeldt, K. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.317163 · Cited by 23
Ramms, B., Patel, S., Sun, X., Pessentheiner, A. R., Ducasa, G. M., Mullick, A. E., Lee, R. G., Crooke, R. M., Tsimikas, S., Witztum, J. L., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.158414 · Cited by 24
“This is in strong contrast to individuals who benefit from lifelong atheroprotective effects of apoC-III loss-of-function mutation (9, 25, 26).”
BackgroundMultiset correlation and factor analysis enables exploration of multi-omics data
Brown, B. C., Wang, C., Kasela, S., Aguet, F., Nachun, D. C., Taylor, K. D., Tracy, R. P., Durda, P., Liu, Y., Johnson, W. C., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100359 · Cited by 25
Recent developments in genome and exome-wide analyses of plasma lipids
Lange, L. A., Willer, C. J., & Rich, S. S. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000159 · Cited by 27
“The APOC3 R19X variant was thought to be a founder variant in the Amish [38], yet it may be more widespread due to its functional impact.”
BackgroundDyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype
Sanin, V., Pfetsch, V., & Köenig, W. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0869-3 · Cited by 31
Genetic Regulatory Networks of Apolipoproteins and Associated Medical Risks
Basavaraju, P., Balasubramani, R., Kathiresan, D. S., Devaraj, I., Babu, K., Vasanthakumar, A., & Moorthi, P. V. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.788852 · Cited by 24
Rare non-coding variants are associated with plasma lipid traits in a founder population
Igartua, C., Mozaffari, S. V., Nicolae, D. L., & Ober, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-16550-8 · Cited by 21
Dowaidar, M. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/rvm3z · Cited by 27
Arab founder variants: Contributions to clinical genomics and precision medicine
AlAbdi, L., Maddirevula, S., Aljamal, B. M., Hamid, H., Almulhim, A., Hashem, M. O., Algoos, Y., Alqahtani, M. F., Albaloshi, S., Alghamdi, M. A., et al. (2024) · Med · doi:10.1016/j.medj.2024.10.005 · Cited by 27
Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA
Brinton, E. A., Eckel, R. H., Gaudet, D., Ballantyne, C. M., Baker, B. F., Ginsberg, H. N., & Witztum, J. L. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119114 · Cited by 22
Ballantyne, C. M., Gaudet, D., Rosenson, R. S., Hegele, R. A., Zhou, R., Melquist, S., Hellawell, J. L., & Leeper, N. J. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.496 · Cited by 23
APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice
Cheng, X., Yamauchi, J., Lee, S., Zhang, T., Gong, Z., Muzumdar, R. H., Qu, S., & Dong, H. H. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.765917 · Cited by 23
Lee, J. H., Oh, H.-K., Choi, B. S., Lee, H. H., Lee, K. J., Kim, U. G., Lee, J., Lee, H.-R., Lee, G. S., Ahn, S. J., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.08.002 · Cited by 19
Karwatowska‐Prokopczuk, E., Lesogor, A., Yan, J., Hoenlinger, A., Margolskee, A., Li, L., & Tsimikas, S. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02297-5 · Cited by 19
“In 2008, it was observed that people with heterozygous loss-of-function mutations in APOC3 had lower triglyceride concentrations and reduced risk of cardiovascular disease [4].”
BackgroundKhera, A. V., & Rader, D. J. (2009) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2009.12.003 · Cited by 19
“As one intriguing example, resequencing efforts in an Amish population identified an ApoC-III premature stop codon associated with lower circulating TG levels, higher HDL-C levels, and decreased atherosclerotic burden as assessed by coronary calcification (Pollin et al. 2008).”
BackgroundImpaired postprandial lipemic response in chronic kidney disease
Saland, J. M., Satlin, L. M., Zalsos-Johnson, J., Cremers, S., & Ginsberg, H. N. (2016) · Kidney International · doi:10.1016/j.kint.2016.02.031 · Cited by 19
Stem Cell–Derived Culture Models of Hepatitis E Virus Infection
Thi, V. L. D., Wu, X., & Rice, C. M. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031799 · Cited by 24
Li, H., Liu, G., Wan, X., Zhou, L., Qin, Z., Ma, X., Su, K., Liu, Y., Yuan, J., Wei, C., et al. (2021) · Hepatology · doi:10.1002/hep.32176 · Cited by 18
Macromolecular Interactions of Lipoprotein Lipase (LPL)
Wheless, A., Gunn, K. H., & Neher, S. B. (2024) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-58843-3_8 · Cited by 20
Novel therapies for severe dyslipidemia originating from human genetics
Gaudet, D. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000281 · Cited by 18
“[18] obtained following a significant exome sequencing effort.”
BackgroundGirelli, D., Piubelli, C., Martinelli, N., Corrocher, R., & Olivieri, O. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.03.019 · Cited by 19
Nedelkov, D. (2017) · Proteomes · doi:10.3390/proteomes5040027 · Cited by 21
“These associations were not detected, or were opposite of that for the other apoC-III proteoforms, suggesting a prognostic and possible mechanistic role for apoC-III2 in dyslipidemia and CVD risk.”
BackgroundInfluentialRecent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention
Quispe, R., Sweeney, T. E., Varma, B., Agarwala, A., & Michos, E. D. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01052-4 · Cited by 18
Huang, M., Han, Y., Zhang, X., Pei, F., Deng, J., Kang, J., & Yan, C. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.11.004 · Cited by 19
Marvel, S. W., Rotroff, D. M., Wagner, M. J., Buse, J. B., Havener, T. M., McLeod, H. L., Motsinger‐Reif, A. A., & The ACCORD/ACCORDion Investigators (2017) · PeerJ · doi:10.7717/peerj.3187 · Cited by 20
“…is adjacent to APOA5, APOA4, APOC3, APOA1, and BUD13, all of which have been previously associated with differences in circulating plasma lipids (Pollin et al., 2008; Marvel et al. (2017), PeerJ, DOI 10.7717/peerj.3187 13/23 Teslovich et al., 2010; Ota et al., 2011; Global Lipids Genetics…”
BackgroundInfluentialA CRISPR edit for heart disease
King, A. (2018) · Nature · doi:10.1038/d41586-018-02482-4 · Cited by 18
Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?
Rhainds, D., Brodeur, M. R., & Tardif, J. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1114 · Cited by 19
“ple, 5% of whom were carriers of the Arg19Stop truncation that abolishes apo C-III synthesis.(78) Arg19Stop carriers have lower”
BackgroundFeingold, K. R. (2017) · Europe PMC (PubMed Central) · Cited by 18
HDL-associated apoCIII plays an independent role in predicting postprandial hypertriglyceridemia
Zhang, T., Tang, X., Mao, L., Chen, J., Kuang, J., Guo, X., Xu, D., Peng, D., & Yu, B. (2020) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2020.02.004 · Cited by 19
An Amish founder population reveals rare-population genetic determinants of the human lipidome
Montasser, M. E., Aslibekyan, S. W., Srinivasasainagendra, V., Tiwari, H. K., Patki, A., Bagheri, M., Kind, T., Barupal, D. K., Fan, S., Perry, J. A., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03291-2 · Cited by 19
Self-citationAn overview of persistent chylomicronemia: much more than meets the eye
Larouche, M., Watts, G. F., Ballantyne, C. M., & Gaudet, D. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000903 · Cited by 17
Amyloid Triangles, Squares, and Loops of Apolipoprotein C-III
de Messieres, M., Huang, R. K., He, Y., & Lee, J. C. (2014) · Biochemistry · doi:10.1021/bi500502d · Cited by 18
Koch, M., Furtado, J. D., Jiang, Z. G., Gray, B. E., Cai, T., Sacks, F. M., Tjønneland, A. M., Overvad, K., & Jensen, M. K. (2017) · Journal of Lipid Research · doi:10.1194/jlr.p073288 · Cited by 18
“Humans with genetically lower apoC-III levels have a more beneficial lipid profile and less subclinical atherosclerosis (7).”
BackgroundWang, J.-S., Chiang, H., Wang, Y.-C., Yeh, H., Ting, I., Liang, C., Wang, M.-C., Lin, C., Hsiao, C.-T., Shen, M., et al. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.05.006 · Cited by 17
Assessing association between protein truncating variants and quantitative traits
Rivas, M. A., Pirinen, M., Neville, M., Gaulton, K. J., Moutsianas, L., Lindgren, C. M., Karpe, F., McCarthy, M. I., & Donnelly, P. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt409 · Cited by 20
Pokharel, Y., Sun, W., Polfus, L. M., Folsom, A. R., HEISS, G. M., Sharrett, A. R., Boerwinkle, E., Ballantyne, C. M., & Hoogeveen, R. C. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.033 · Cited by 18
Development of Antisense Drugs for Dyslipidemia
Yamamoto, T., Wada, F., & Harada‐Shiba, M. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv16001 · Cited by 19
Primary genetic disorders affecting high density lipoprotein (HDL)
Kosmas, C. E., Silverio, D., Sourlas, A., Garcia, F., Montan, P. D., & Guzman, E. (2018) · Drugs in Context · doi:10.7573/dic.212546 · Cited by 17
Milonas, D., & Τζιόμαλος, Κ. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1582028 · Cited by 17
Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease
Tsimikas, S. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01345-4 · Cited by 16
Metadata
- Authors
- Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., Mitchell, B. D., Miller, M., O'Connell, J. R., & Shuldiner, A. R.
- Affiliations
- University of Maryland, Baltimore (US)
- Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
- Corresponding author
- Pollin, Toni I.
- ORCID
- Venue
- Science
- Published
- 2008-12-12
- Volume
- 322
- Issue
- 5908
- Pages
- 1702-1705
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2673993
- OpenAlex
- W2061100095
- Semantic Scholar
- d46146fa9f89ec4722b99bade97f6a1d685409c0
- Cited by
- 688
- References
- 34
- Citations by year
- 2026: 31 · 2025: 33 · 2024: 30 · 2023: 30 · 2022: 30 · 2021: 41 · 2020: 38 · 2019: 36 · 2018: 52 · 2017: 51 · 2016: 54 · 2015: 49 · 2014: 55 · 2013: 43 · 2012: 23
- FWCI
- 22.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (R01-AG-18728, R01AG018728)
- National Heart, Lung, and Blood Institute (U01HL72515, U01HL084756, U01HL072515, R01HL088119)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK072488)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR046838)
- National Center for Research Resources (M01RR016500, M01RR000052, M01RR 16500)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- apolipoprotein C-III, plasma lipid profile, triglycerides, HDL cholesterol, LDL cholesterol, coronary artery calcification, subclinical atherosclerosis, cardioprotection, coronary artery disease, lipolysis
- MeSH terms
- Adult, Cholesterol, Christianity, Coronary Artery Disease, Dietary Fats, Fasting, Female, Haplotypes, Heterozygote, Humans, Lipids, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Mutation, Pedigree, Pennsylvania, Risk Factors, Triglycerides, Linkage Disequilibrium, Polymorphism, Single Nucleotide, Apolipoprotein C-III, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.